Prostate Cancer Clinical Trials in High Point, NC

Prostate Cancer Clinical Trials in High Point, NC

View the best 10 prostate cancer medical studies in High Point, North Carolina. Access promising new therapies by applying to a High Point-based Prostate Cancer clinical trial.

Trials in High Point, North Carolina

Here are the top 10 medical studies for prostate cancer in High Point, North Carolina

Image of Mayo Clinic Hospital in Phoenix, United States.

ADT +1 More

Hormone Therapy

Recruiting1 awardPhase 3
This trial is researching if a combination of ADT and darolutamide can help men with prostate cancer at high risk of biochemical recurrence (BCR) live longer without their cancer getting worse.
Image of University of Alabama at Birmingham in Birmingham, United States.

Enzalutamide +1 More

Antiandrogen

Recruiting1 awardPhase 3
This trial will test whether adding the drug enzalutamide to leuprolide helps patients with high-risk prostate cancer that has come back after surgery or radiotherapy.
Image of City of Hope National Medical Center in Duarte, United States.

AMG 509

Protein Kinase Inhibitor

Recruiting1 awardPhase 1
This trial is testing a new drug called AMG 509 in adults to see if it is safe and to find the best dose. The study will monitor how people react to different doses.
Image of Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem, United States.

Docetaxel +1 More

Fatty Acid Synthase Inhibitor

Recruiting1 awardPhase 2
This trial is testing if adding omeprazole, a common stomach acid reducer, can help prostate cancer patients who are not responding well to their current treatments with cabazitaxel or docetaxel. Omeprazole may block an enzyme that helps cancer cells grow, potentially making the cancer drugs more effective. Omeprazole has been widely studied for its interactions with other drugs.
Image of Rocky Mountain Regional VA Medical Center, Aurora, CO in Aurora, United States.

High dose testosterone

Hormone Therapy

Recruiting3 awardsPhase 2
This trial will test whether intermittent high-dose testosterone therapy can shrink tumors in men with DNA repair deficiency.
Image of NCT02489318 in Homewood, United States.

Apalutamide +1 More

Antiandrogen

Recruiting1 awardPhase 3
This trial will study whether the addition of apalutamide to androgen deprivation therapy (ADT) can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC).
Image of University of Michigan Rogel Cancer Center in Ann Arbor, United States.

Oncotype Dx Genomic Prostate Score (GPS) +3 More

Gene Expression Classifier

Recruiting1 award6 criteria
This trial studies how GEC testing can improve prostate cancer care by analyzing gene activity to better predict cancer aggressiveness. It targets prostate cancer patients to help make more informed treatment decisions.
Image of Chesapeake Urology Research Associates in Towson, United States.

lutetium Lu 177 vipivotide tetraxetan +1 More

Procedure

Recruiting1 awardPhase 1 & 2
This trial tests a new combination of treatments for metastatic prostate cancer. Participants are randomized to two arms to assess safety and effectiveness.
Image of City of Hope National Medical Center in Duarte, United States.

Olaparib +2 More

PARP Inhibitor

Recruiting3 awardsPhase 2
This trial is testing a new cancer treatment for men with metastatic castration resistant prostate cancer. It is a 1:1:1 randomized open-label multicenter phase II study, which means that patients will be randomly assigned to one of three different treatment groups. The study will take place at multiple centers, and patients will be observed over the course of the trial.
Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

Pembrolizumab

Checkpoint Inhibitor

Recruiting2 awardsPhase 2
This trial is testing the efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer. The study will also compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab.

Phase 3 Trials

Trials With No Placebo

View More Related Trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.